Research programme: phosphatidylinositol-3-kinase inhibitors - Onconova

Drug Profile

Research programme: phosphatidylinositol-3-kinase inhibitors - Onconova

Alternative Names: ON 146; ON 146040

Latest Information Update: 14 Jul 2014

Price : $50

At a glance

  • Originator Onconova Therapeutics
  • Class Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Burkitt's lymphoma; Chronic myeloid leukaemia; Mantle-cell lymphoma; Multiple myeloma

Most Recent Events

  • 20 Mar 2014 Preclinical trials in Multiple myeloma in USA (unspecified route)
  • 20 Mar 2014 Preclinical trials in Mantle cell lymphoma in USA (unspecified route)
  • 20 Mar 2014 Preclinical trials in Chronic myeloid leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top